Comparing Different Donor Sites After Vascularized Lymph Node Transfer to the Lymphedematous Upper Limb: A Systematic Review and Meta-analysis of Clinical Outcomes.

BACKGROUND: Vascularized lymph node transfer (VLNT) involves the microvascular transplantation of functional lymph nodes from a donor site into a limb affected by lymphedema to restore the normal flow of lymphatic fluid. Despite the increasing clinical experience with VLNT, there remains insufficient data to support its routine use in clinical practice. Here, we aim to evaluate the effectiveness and safety of VLNTs for upper limb lymphedema and compare clinical outcomes when using different donor sites. METHODS: We carried out a systematic search of the literature through PubMed and Scopus databases for studies on VLNT for upper limb lymphedema. Primary and secondary outcomes included circumference reduction rate (CRR) and infection reduction rate by postoperative cellulitis episodes for the efficacy and safety of VLNT. Pooled analysis was performed using the inverse variance weighting meta-analysis of single means using the meta package in R software. Subgroup analyses were performed for donor and recipient sites, age groups, follow-ups, and symptom durations. Quality assessment was performed using the Newcastle-Ottawa Scale for nonrandomized studies. RESULTS: A total of 1089 studies were retrieved from the literature, and 15 studies with 448 upper limb lymphedema patients who underwent VLNT were included after eligibility assessment. The mean CRR was 34.6 (18.8) and the mean postoperative cellulitis episodes per year was 0.71 (0.7). The pooled analysis of CRR was 28.4% (95% confidence interval, 19.7-41.1) and postoperative cellulitis episodes showed a mean of 0.59 (95% confidence interval, 0.36-0.95) using the random-effect model. Subgroup analyses showed significant group differences in recipient site for CRR and postoperative cellulitis episodes with the wrist comprising the highest weights, and patients younger than 50 years showing a lower postoperative infection. CONCLUSIONS: Vascularized lymph node transfer using gastroepiploic flaps at the wrists has shown a significant difference in reductions of limb circumference and cellulitis episodes in upper limb lymphedema patients when compared with other donor sites. However, further prospective studies are needed to consolidate this finding.

The Difference in Scar-Related Quality of Life in Open Versus Closed Septorhinoplasty.

INTRODUCTION: The open and closed techniques are the main surgical techniques to perform septorhinoplasty. Although the open technique offers a better view of the pertinent anatomy and facilitates surgical access, it creates an external scar that could affect patients' satisfaction and quality of life (QoL). This study aims to compare the open and closed techniques using the SCAR-Q patient-reported outcome measure. METHODS: In this retrospective study, we have included patients who had their nasal surgery one year ago, in the period between April 2020 and April 2021. The SCAR-Q assessment tool to study patients' satisfaction with appearance, symptoms, and psychological impact of open and closed septorhinoplasty techniques. RESULTS: A total of 77 patients were included in this analysis. Of these, 39 (50.6%) patients underwent a closed septorhinoplasty, and 38 (49.4%) patients underwent an open approach. The mean (SD) age was 29.6 (8.1) years, and most patients were females (59.7%). The overall SCAR-Q questionnaire responses were very positive across all scales in our cohort, the median (IQR) scores were 91.0 (73.0-100.0) for the appearance scale, 89.0 (70.0-100.0) for the symptoms scale, and 100.0 (87.0-100.0) for the psychological impact scale. However, we have found no differences in SCAR-Q scores regarding appearance, symptoms, and psychological impact between open and closed septorhinoplasty. CONCLUSION: We have found no significant differences in QoL between open and closed techniques of septorhinoplasty. Larger studies are needed to further validate this finding.

Discovery of a Small Molecule Promoting Mouse and Human Osteoblast Differentiation via Activation of p38 MAPK-ß.

Disorders of bone healing and remodeling are indications with an unmet need for effective pharmacological modulators. We used a high-throughput screen to identify activators of the bone marker alkaline phosphatase (ALP), and discovered 6,8-dimethyl-3-(4-phenyl-1H-imidazol-5-yl)quinolin-2(1H)-one (DIPQUO). DIPQUO markedly promotes osteoblast differentiation, including expression of Runx2, Osterix, and Osteocalcin. Treatment of human mesenchymal stem cells with DIPQUO results in osteogenic differentiation including a significant increase in calcium matrix deposition. DIPQUO stimulates ossification of emerging vertebral primordia in developing zebrafish larvae, and increases caudal fin osteogenic differentiation during adult zebrafish fin regeneration. The stimulatory effect of DIPQUO on osteoblast differentiation and maturation was shown to be dependent on the p38 MAPK pathway. Inhibition of p38 MAPK signaling or specific knockdown of the p38-ß isoform attenuates DIPQUO induction of ALP, suggesting that DIPQUO mediates osteogenesis through activation of p38-ß, and is a promising lead candidate for development of bone therapeutics.